报价延迟最少15分钟:2026/10/20 23:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.515 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.06/--
|
|
企业价值
2.20M
|
| 资产负债 |
|
每股账面净值
-1.99
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada. |
